106 related articles for article (PubMed ID: 12494056)
1. [Effect of eprosartan on left ventricular diastolic function and cerebral hemodynamics in patients with hypertension].
Markova LI; Radzevich AE; Koren'kov VV; Belavina NI; Griabina NA; Zharova OIu
Kardiologiia; 2002; 42(10):41-4. PubMed ID: 12494056
[TBL] [Abstract][Full Text] [Related]
2. Effects of eprosartan on diastolic function and neurohormones in patients with hypertension and diastolic dysfunction.
Voors AA; van de Wal RM; Hartog JW; Vijn RG; Hummel YM; Plokker TW; van Veldhuisen DJ; Jaarsma W
Cardiovasc Drugs Ther; 2010 Feb; 24(1):33-40. PubMed ID: 20229056
[TBL] [Abstract][Full Text] [Related]
3. [An AT-II blocker in patients with type II diabetes and arterial hypertension].
Ametov AS; Demidova TIu; Kosykh SA
Klin Med (Mosk); 2006; 84(2):50-5. PubMed ID: 16613007
[TBL] [Abstract][Full Text] [Related]
4. [Elevation pressure in morning hours in patients with essential hypertension: effect therapy with eprosartan for leading stress tests].
Shevchenko OP; Praskurnichiĭ EA; Makarova SV; Samartsev GA; Lapina EIa
Kardiologiia; 2004; 44(3):58-63. PubMed ID: 15489829
[No Abstract] [Full Text] [Related]
5. Hemodynamic and cardiac effects of chronic eprosartan and moxonidine therapy in stroke-prone spontaneously hypertensive rats.
Mukaddam-Daher S; Menaouar A; Paquette PA; Jankowski M; Gutkowska J; Gillis MA; Shi YF; Calderone A; Tardif JC
Hypertension; 2009 May; 53(5):775-81. PubMed ID: 19273740
[TBL] [Abstract][Full Text] [Related]
6. [Effect of eprosartan on microcirculation and blood rheology in patients with hypertensive disease].
Markova LI; Koren'kov VV; Shakhova NI; Radzevich AE
Kardiologiia; 2004; 44(2):27-9. PubMed ID: 15029132
[TBL] [Abstract][Full Text] [Related]
7. [Comparison of eprosartan and captopril in left ventricular systolic dysfunction: relation of efficacy to myocardial viability].
Shalaev SV; Metlitskaia EV; Teffenberg DV; Shanaurina NV; Petrik ES; Volkova SIu
Kardiologiia; 2004; 44(1):10-3. PubMed ID: 15029143
[TBL] [Abstract][Full Text] [Related]
8. [Antihypertensive treatment with eprosartan mesilate of patients in acute and late periods of ischemic stroke].
Gusev EI; Martynov MIu; Boĭko AN; Petukhov EB; Makarov AN
Zh Nevrol Psikhiatr Im S S Korsakova; 2003; 103(11):15-20. PubMed ID: 14681960
[TBL] [Abstract][Full Text] [Related]
9. Association between eprosartan-based hypertension therapy and improvement in cognitive function score: long-term follow-up from the OSCAR observational study.
Hanon O; Lee YS; Pathak A;
J Renin Angiotensin Aldosterone Syst; 2015 Jun; 16(2):366-73. PubMed ID: 23748626
[TBL] [Abstract][Full Text] [Related]
10. Eprosartan: a review of its use in the management of hypertension.
Robins GW; Scott LJ
Drugs; 2005; 65(16):2355-77. PubMed ID: 16266204
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of eprosartan in combination with HCTZ in patients with essential hypertension.
Sachse A; Verboom CN; Jäger B
J Hum Hypertens; 2002 Mar; 16(3):169-76. PubMed ID: 11896506
[TBL] [Abstract][Full Text] [Related]
12. Eprosartan versus enalapril in elderly patients with hypertension: a double-blind, randomized trial.
Ruilope L; Jäger B; Prichard B
Blood Press; 2001; 10(4):223-9. PubMed ID: 11800061
[TBL] [Abstract][Full Text] [Related]
13. [Effect of nebivolol on remodeling of the heart and vessels and the state of hemodynamics in patients with hypertension].
Gromnatskiĭ NI; Dius'mikeeva NB
Kardiologiia; 2002; 42(10):27-30. PubMed ID: 12494053
[TBL] [Abstract][Full Text] [Related]
14. Introduction: The pharmacological profile of eprosartan--implications for cerebrovascular and cardiovascular risk reduction.
de la Sierra A; Ram CV
Curr Med Res Opin; 2007 Nov; 23 Suppl 5():S1-3. PubMed ID: 18093407
[TBL] [Abstract][Full Text] [Related]
15. Angiotensin blockade with eprosartan: vascular and functional implications.
Ram CV
Curr Med Res Opin; 2007 Nov; 23 Suppl 5():S5-11. PubMed ID: 18093408
[TBL] [Abstract][Full Text] [Related]
16. Effects of enalapril and eprosartan on the renal vascular nitric oxide system in human essential hypertension.
Delles C; Jacobi J; John S; Fleischmann I; Schmieder RE
Kidney Int; 2002 Apr; 61(4):1462-8. PubMed ID: 11918753
[TBL] [Abstract][Full Text] [Related]
17. Eprosartan provides safe and effective long-term maintenance of blood pressure control in patients with mild to moderate essential hypertension.
Levine B
Curr Med Res Opin; 2001; 17(1):8-17. PubMed ID: 11464450
[TBL] [Abstract][Full Text] [Related]
18. Effects of eprosartan on mitochondrial membrane potential and H2O2 levels in leucocytes in hypertension.
Labiós M; Martínez M; Gabriel F; Guiral V; Ruiz-Aja S; Beltrán B; Muñoz A
J Hum Hypertens; 2008 Jul; 22(7):493-500. PubMed ID: 18385744
[TBL] [Abstract][Full Text] [Related]
19. A dose-response study to assess the renal hemodynamic, vascular, and hormonal effects of eprosartan, an angiotensin II AT1-receptor antagonist, in sodium-replete healthy men.
Ilson BE; Boike SC; Martin DE; Freed MI; Zariffa N; Jorkasky DK
Clin Pharmacol Ther; 1998 Apr; 63(4):471-81. PubMed ID: 9585802
[TBL] [Abstract][Full Text] [Related]
20. Eprosartan mesylate effectively reduces systolic and diastolic blood pressure in a Canadian primary care setting.
Conter HS; McKay DW; Reiz RJ
Can J Cardiol; 2004 Oct; 20 Suppl C():6C-10C. PubMed ID: 16807617
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
